Bli medlem
Bli medlem

Du är här

2016-05-12

Karo Pharma: INTERIM REPORT JANUARY - MARCH 2016

FIRST QUARTER

· Net sales amounted to MSEK 82.3 (0.4)
· Earnings before depreciation were MSEK 9.3 (-14.9)
· Earnings per share amounted to SEK 0.06 (-0.42)
· Cash and cash equivalents at period end amounted to MSEK 11.2
(32.2)

· The name of the Group was changed to Karo Pharma to better
re-flect current operations

SIGNIFICANT EVENTS AFTER PERIOD END

· Two share issues totaling MSEK 280 were carried out. The issues,
which were oversubscribed by 210 per cent, were completed after
period end, hence not being reflected in the cash position. Executive
Chairman Anders Lönner underwrote over 97 percent of the rights issue
of MSEK 250.

CONFERENCE CALL / AUDIOCAST TODAY AT 10.00 A.M. CET
A presentation of the report (in Swedish) will take place today at 10
a.m. The presentation and slides are available through the corporate
website www.karopharma.se or by telephone 08-505 564 74. Questions
may be submitted over the internet or by the telephone.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Henrik Palm, CFO, +46 70 540 4014 or henrik.palm@karopharma.se
ABOUT KARO PHARMA
Karo Pharma is a healthcare company that develops and markets products
to pharmacies and directly to healthcare providers. The share is
listed on Nasdaq Stockholm.

The information in this report is such that Karo Pharma is required to
disclose under the Swedish Securi-ties Market Act. The information
was disclosed on May 12, 2016 at 8.30 a.m. CET.

-----------------------------------------------------------
http://news.cision.com/karo-pharma/r/interim-report-january---march-2016...
http://mb.cision.com/Main/72/2007552/514779.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.